EUVIMEDEUVIMED entdecken
Open Access

Plasma Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Biomarkers of Cognitive Decline in People With Human Immunodeficiency Virus

Shibani S Mukerji iD, Petra Bachanová, Hemi Park, Linzy V Rosen, Rommi Kashlan, Pia Kivisäkk, Albert M Anderson, Felicia C Chow, Kunling Wu, Raha M Dastgheyb, Leah H Rubin, Katherine Tassiopoulos und 2 weitere

The Journal of Infectious Diseases · 2025

DOI: 10.1093/infdis/jiae623 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Shibani S Mukerji und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. Hauptthemen laut MEDLINE: Neurofilament Proteins, Glial Fibrillary Acidic Protein, HIV Infections, Cognitive Dysfunction. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMHD NIH HHS, National Institute of Allergy and Infectious Diseases, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We examined the relationship between neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) and cognition in people with human immunodeficiency virus (HIV) at baseline and longitudinally.

Methods

Plasma and clinical data were available from virally suppressed people with HIV (PWH) aged ≥45 years in the AIDS Clinical Trials Group HAILO study. Four neuropsychological assessments standardized and averaged (NPZ-4) represented cognition. Plasma collection date marked baseline; slope summarized longitudinal NPZ-4 changes. Linear regressions examined biomarkers associations with baseline NPZ-4 and longitudinal change.

Results

The study included 503 participants with a median age of 52 (interquartile range [IQR, 48–57]) years and observation of 6 (IQR, 5–7) years, and 26% had baseline cognitive impairment defined by HAILO. Cross-sectionally, higher NfL (β = −.76, P < .01) and GFAP (β = −.44, P = .02) were associated with worse NPZ-4. Longitudinally, the median NPZ-4 slope was 0.003 (IQR, −0.06 to 0.06) units/year with 48% demonstrating cognitive decline. Higher NfL (β = −.08, P < .01), but not GFAP (β = −.03, P = .08), was associated with cognitive decline.

Conclusions

NfL and GFAP were associated with worse cognition cross-sectionally; only NfL was associated with cognitive decline. Their clinical utility remains uncertain given small effect sizes and should be studied in populations with more rapid decline.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neurofilament ProteinsGlial Fibrillary Acidic ProteinHIV InfectionsCognitive DysfunctionHumansBiomarkersMiddle AgedMaleFemaleLongitudinal StudiesCross-Sectional StudiesNeuropsychological Tests

Stichwörter der Autor:innen

NPZ-4 scoreagingcognitioncognitive declineplasma biomarkers

Substanzen

Neurofilament ProteinsBiomarkersGlial Fibrillary Acidic Proteinneurofilament protein LGFAP protein, human

Autor:innen und Institutionen

  • Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Vaccine and Immunotherapy Center, Massachusetts General Hospital, Boston, Massachusetts.
  • Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts.
  • Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia.
  • Departments of Neurology and Medicine (Infectious Diseases) and Weill Institute for Neurosciences, University of California, San Francisco, California.

ORCID-Profile: Shibani S Mukerji, Robert A Parker

Förderung

  • NIMHD NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • NIH HHS
  • NIMH NIH HHS
  • Harvard University Center
  • for AIDS Research
  • NIAID NIH HHS
  • NIDA NIH HHS

Zitieren

APA

Mukerji, S. S., Bachanová, P., Park, H., Rosen, L. V., Kashlan, R., Kivisäkk, P., Anderson, A. M., Chow, F. C., Wu, K., Dastgheyb, R. M., Rubin, L. H., Tassiopoulos, K., Parker, R. A., & Hyle, E. P. (2025). Plasma Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Biomarkers of Cognitive Decline in People With Human Immunodeficiency Virus. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae623

Vancouver

Mukerji SS, Bachanová P, Park H, Rosen LV, Kashlan R, Kivisäkk P, et al. Plasma Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Biomarkers of Cognitive Decline in People With Human Immunodeficiency Virus. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiae623

BibTeX
@article{Mukerji2025,
  author = {Mukerji, Shibani S and Bachanová, Petra and Park, Hemi and Rosen, Linzy V and Kashlan, Rommi and Kivisäkk, Pia and Anderson, Albert M and Chow, Felicia C and Wu, Kunling and Dastgheyb, Raha M and Rubin, Leah H and Tassiopoulos, Katherine and Parker, Robert A and Hyle, Emily P},
  title = {Plasma Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Biomarkers of Cognitive Decline in People With Human Immunodeficiency Virus},
  journal = {The Journal of Infectious Diseases},
  year = {2025},
  doi = {10.1093/infdis/jiae623}
}
Kostenlos starten →